943541-40-0

Basic information

• Product Name: ethyl2,2-difluoro-2-(quinolin-6-yl)acetate
• Synonyms: ethyl2,2-difluoro-2-(quinolin-6-yl)acetate;6-[(Ethoxycarbonyl)difluoromethyl]quinoline;Ethyl difluoro(quinolin-6-yl)acetate;6-Quinolineacetic acid, α,α-difluoro-, ethyl ester
• CAS NO: 943541-40-0
• Molecular Formula: C₁₃H₁₁F₂NO₂
• Molecular Weight: 251.23
• Mol File: 943541-40-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 348.7 °C at 760 mmHg
• Flash Point: 164.7 °C
• Appearance: /
• Density: 1.269 g/cm³
• Vapor Pressure: 4.93E-05mmHg at 25°C
• Refractive Index: 1.546
• PKA: 4.08±0.10(Predicted)
• CAS DataBase Reference: ethyl2,2-difluoro-2-(quinolin-6-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl2,2-difluoro-2-(quinolin-6-yl)acetate(943541-40-0)
• EPA Substance Registry System: ethyl2,2-difluoro-2-(quinolin-6-yl)acetate(943541-40-0)

Safety Data

• Hazardous Substances Data: 943541-40-0(Hazardous Substances Data)

Usage

General Description

Ethyl2,2-difluoro-2-(quinolin-6-yl)acetate is a chemical compound characterized by the presence of a quinolin-6-yl group and two fluorine atoms. The presence of difluoro in its name indicates that there are two fluorine atoms attached to a carbon atom. The term "ethyl" refers to the ethyl group (-C2H5) present in the compound, and the word "acetate" connotes it as an ester of acetic acid. As a niche industrial chemical, it may find use in various chemical synthesis processes and in the development and manufacturing of pharmaceuticals or other fine chemicals. The specific properties, toxicology, and safety measures related to this compound would typically be determined by detailed laboratory analysis and standard safety assessments.

InChI:InChI=1/C13H11F2NO2/c1-2-18-12(17)13(14,15)10-5-6-11-9(8-10)4-3-7-16-11/h3-8H,2H2,1H3

Upstream product

• 13327-31-6 6-iodoquinoline 
• 383-62-0 ethyl 2-chloro-2,2-difluoroacetate 
• 5332-25-2 6-bromoquinoline 
• 1093204-29-5 ethyl 2-oxo-2-(6-quinolyl)acetate 
• 667-27-6 Ethyl bromodifluoroacetate 

Downstream Products

• 1093204-35-3 sodium 2,2-difluoro-2-(quinolin-6-yl)acetate 
• 1151800-43-9 6-[(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-difluoro-methyl]-quinoline 
• 1256455-26-1 5-(difluoro(quinolin-6-yl)methyl)-4-(iminotriphenylphosphorano)-4H-1,2,4-triazole-3-thiol 
• 1256487-41-8 5-(difluoro(quinolin-6-yl)methyl)-4-(iminotriphenylphosphorano)-4H-1,2,4-triazole-3-thiol 
• 1256487-35-0 VRT-846198 
• 1256487-42-9 1-(3-(difluoro(quinolin-6-yl)methyl)-[1,2,4]triazolo[3,4-d][1,3,4]thiadiazol-6-yl)-1,3-bis(1-methyl-1H-pyrazol-4-yl)urea 
• 1256455-21-6 C₁₈H₁₃F₂N₇S 
• 943540-75-8 JNJ-38877605 
• 943541-39-7 2,2-difluoro-2-(quinolin-6-yl)acetic acid hydrazide 

Relevant articles and documents

Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors

Herein, we report a novel series of highly potent and selective triazolothiadiazole c-Met inhibitors. Starting with molecule 5, we have applied structure-based drug design principles to identify the triazolothiadiazole ring system. We successfully replaced the metabolically unstable phenolic moiety with a quinoline group. Further optimization around the 5,6 bicyclic moiety led to the identification of 21. Compound 21 suffered from PDE3 selectivity issues and subsequent, structurally informed design led to the discovery of compound 23. Compound 23 has exquisite kinase selectivity, excellent potency, favorable ADME profile, and showed dose-dependent antitumor efficacy in a SNU-5 gastric cancer xenograft model.

AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITOR OF C-MET PROTEIN KINASE

The present invention relates to anhydrous and hydrated forms of Compound 1, which qre useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.

HETEROCYCLIC OXIME COMPOUNDS

The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).